Seaweed supplement shows promise for cancer-related fatigue in small pilot trial
NCT ID NCT06295588
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This pilot study tests whether taking a seaweed supplement called fucoidan for 8 to 16 weeks can reduce fatigue and inflammation in cancer survivors. Researchers will enroll 40 adults who have completed cancer treatment within the last 10 years and still feel tired. The main goal is to see if the study is feasible, but they will also measure changes in fatigue, frailty, and blood markers of inflammation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- fucoidan (a seaweed supplement)
- What this could lead to
- If it works, this could point toward a natural supplement to ease fatigue and inflammation in cancer survivors.
- What could go wrong
- This is a small, early pilot study with only 40 people. It's testing feasibility, not yet effectiveness, and results may not apply to all survivors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Survivors of cancer * Age 18 or older * Speak and understand English * Have completed surgery, radiation, and/or systemic intravenous anticancer therapy (e.g., chemotherapy, targeted therapy, immunotherapy) ≤10 years prior to enrollment. * Have a baseline level of fatigue, as determined by reporting a score of 4 or higher for the question, "In the last week, how bad was your worst fatigue on a scale from 0-10?" * Be willing to commit to the fucoidan supplement dosing and delivery method, to complete evaluation instruments, and to attend all study visits. * Completed Informed Consent Exclusion Criteria: * Current warfarin or other anti-coagulation medication use. * Current use of supplements that contain fucoidan * Any allergy to fucoidan * Be diagnosed with a major psychiatric illness requiring hospitalization within the last year. * Be diagnosed with dementia. * Be pregnant or nursing
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fatigue are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercising with your baby reshape postpartum recovery?
- Can a berry extract help athletes bounce back after brutal workouts?
- Can PET scans reveal hidden heart inflammation after a stroke?
- After a stroke, does the heart inflame? MRI study probes the link
- 150,000 children to be tracked from birth to old age in massive health study
- Blood clues in depression: immune signals may flag who benefits from SSRIs